EDD: honoraria: Takeda; consulting fees: Takeda, and BeiGene. TI: speakers fee: Takeda; consulting fees: Takeda. SH: honoraria: ADC Therapeutics, Affimed, Aileron, Celgene, Crispr Therapeutics, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Seattle Genetics, Trillium Therapeutics, and Verastem/SecuraBio; consulting fees: Acrotech Biopharma, ADC Therapeutics, Astex, Auxilus Pharma, Merck, C4 Therapeutics, Celgene, Cimieo Therapeutics, Daiichi Sankyo, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, SecuraBio, Shoreline Biosciences, Inc, Takeda, Trillium Therapeutics, Tubulis, Verastem/SecuraBio, Vividion Therapeutics, and Yingli Pharma Limited; grants or funds: NIH/NCI Cancer Center Support Grant P30 CA008748; a Specialized Center for Research grant from the Leukemia and Lymphoma Society (7026-21 [S.M.H.]); a Career Development Program Award from the Leukemia and Lymphoma Society (2332-20 [A.J.M.]), and Nonna’s Garden Foundation. SI: honoraria: Target Oncology, BioCure, ASTCT, ISLH; consulting fees: Seagen, Pfizer, Acrotech, DrenBio, and Yingli; grants or funds: Merck, Seagen, Innate, Legend, CRISPR, Acrotech, AstraZeneca, Myeloid, Ono, and DrenBio. RA: grants or funds: Institution Research Support. NLB: advisory council or committee: ADC Therapeutics; Foresight Diagnostics; Kite; Roche/Genentech; and Seattle Genetics; grants or funds: ADC Therapeutics; Autolus; Bristol Myers Squibb (BMS)/Celgene; Forty Seven; Gilead/Kite Pharma; Janssen; Merck; Millennium; Pharmacyclics; Roche/Genentech; and Seattle Genetics. WSK: consulting fees: Celltrion; grants or funds: Sanofi, Beigene, Donaga, Boryong, and Roche. TF: honoraria: Seagen, and Takeda; consulting fees: Seagen, and Takeda. GG: advisory council or committee: Takeda, Genmab, Roche, Kite-Gilead, Italfarmaco, and Ideogen; training activity: Clinigen, Incyte, Novartis, and Takeda; support for attending meetings: Sandoz, Beigene, and Janssen. DB: advisory council or committee: Takeda, Roche, Janssen-Cilag, Gilead Sciences, and Genmab; consulting fees: Takeda, and Roche. BP: honoraria: Takeda. AS: employment: Cellectar Biosciences; ownership of stock/shares: Cellectar Biosciences. AI: advisory council or committee: AbbVie, Janssen, Celgene, Novartis, Takeda, Pfizer, and Roche; consulting fees: AbbVie, Janssen, Celgene, Novartis, Takeda, Pfizer, and Roche. PLZ: honoraria: Takeda, Gilead, MSD, Novartis, Incyte, BeiGene, AbbVie, Roche, Kyowa Kirin, AstraZeneca, Janssen, and Regeneron; consulting fees: Takeda, Gilead, Merck Sharp & Dohme, Novartis, Incyte, BeiGene, AbbVie, Roche, Kyowa Kirin, AstraZeneca, Janssen, and Regeneron. MT: advisory council or committee: Takeda, BMS, Incyte, AbbVie, Amgen, Roche, Gilead Sciences, Janssen, MorphoSys, Novartis, Genmab, SOBI, Autolus, and Caribou Biosciences; honoraria: Janssen, Gilead Sciences, Takeda, BMS, Amgen, AbbVie, Roche, MorphoSys, and Novartis. ML: ownership of stock/shares: Takeda. CD: employment: Takeda; ownership of stocks/shares: Takeda, and Seagen. MF: employment: Seagen; ownership of stock/shares: Seagen. KF: employment: Seagen; ownership of stock/shares: Seagen KJS: advisory council or committee: BMS; honoraria: BMS, Seagen, and AbbVie; consulting fees: Seagen; grants or funds: BMS, and Roche (institutional); steering committee: DSMC: Regeneron. LT, JHC, IC, AH, SL, DJ, and JWF all have no potential conflict of interest to report.